Neovasc Inc. (NVCN) is a Pharmaceuticals and Biotechnology company listed on NASDAQ. There were no new wire items for NVCN in the last 30 days. The most recent was published Apr 24, 2024.
Latest news
25 items- PRVolato Announces Changes to Board CompositionVolato to Announce First Quarter 2024 Results on Wednesday, May 15, 2024 Volato Group, Inc. ("Volato," or the "Company") (NYSE:SOAR) today announced that it has appointed Christopher G. Burger and Fred A. Colen to the Company's Board of Directors. As part of this announcement, Joan Sullivan Garrett, Katherine Arris-Wilson, Peter Mirabello, and Dana H. Born have stepped down from the Company's Board of Directors without disagreement. The company is decreasing the size of its board from seven to five members, three of whom are Independent Directors. Fred Colen will serve as an independent director and Chair of the Audit Committee and has been designated as a financial expert. Chris Burger
- SECSEC Form EFFECT filed by Neovasc Inc.EFFECT - NEOVASC INC (0001399708) (Filer)
- SECSEC Form 15F-12B filed by Neovasc Inc.15F-12B - NEOVASC INC (0001399708) (Filer)
- SECSEC Form 6-K filed by Neovasc Inc.6-K - NEOVASC INC (0001399708) (Filer)
- SECSEC Form 6-K filed by Neovasc Inc.6-K - NEOVASC INC (0001399708) (Filer)
- SECSEC Form RW filed by Neovasc Inc.RW - NEOVASC INC (0001399708) (Filer)
- SECSEC Form F-10POS filed by Neovasc Inc.F-10POS - NEOVASC INC (0001399708) (Filer)
- SECSEC Form POS AM filed by Neovasc Inc.POS AM - NEOVASC INC (0001399708) (Filer)
- SECSEC Form S-8 POS filed by Neovasc Inc.S-8 POS - NEOVASC INC (0001399708) (Filer)
- SECSEC Form 25-NSE filed by Neovasc Inc.25-NSE - NEOVASC INC (0001399708) (Subject)
- SECSEC Form 6-K filed by Neovasc Inc.6-K - NEOVASC INC (0001399708) (Filer)
- NEWSNeovasc Announces Q4 And FY22 Financial Results And Provides Corporate Update; FY22 Revenue $$3.8M Vs $2.55M YoY; FY22 EPS $(15.07) Vs $(9.88) YoYFinancial Results for the Fiscal Year Ended December 31, 2022 Revenues increased by 49% to $3,805,017 for the year ended December 31, 2022, compared to revenues of $2,547,406 for the same period in 2021. The cost of goods sold for the year ended December 31, 2022 was $773,834 compared to $555,697 for the same period in 2021. The overall gross margin for the year ended December 31, 2022 was 80%, compared to 78% gross margin for the same period in 2021. Total expenses for the year ended December 31, 2022 were $37,177,906 compared to $33,101,250 for 2021, representing an increase of $4,076,656. The operating losses and comprehensive losses for the year ended December 31, 2022 were $34,146,7
- SECSEC Form 6-K filed by Neovasc Inc.6-K - NEOVASC INC (0001399708) (Filer)
- PRNeovasc Shareholders Approve Acquisition by Shockwave MedicalVancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ:NVCN) (TSX:NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting").The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareholders o
- PRNeovasc Shareholders Approve Acquisition by Shockwave MedicalVANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 97.36% of the votes cast by the shareh
- NEWSNeovasc Shareholders Approve Acquisition By Shockwave Medicalhttps://neovasc.com/newsreleases/neovasc-shareholders-approve-acquisition-by-shockwave-medical/
- SECSEC Form 6-K filed by Neovasc Inc.6-K - NEOVASC INC (0001399708) (Filer)
- NEWSThe German Institute For Hospital Remuneration System Has Awarded The Neovasc's Reducer, A Ce-marked Medical Device For Refractory Angina, Nub Status 1 Designation For 2023.
- SECSEC Form 6-K filed by Neovasc Inc.6-K - NEOVASC INC (0001399708) (Filer)
- PRNeovasc Announces German Reimbursement RenewalVANCOUVER and MINNEAPOLIS, Feb. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. ("Neovasc" or "the Company") (NASDAQ , TSX : NVCN) today announced the German Institute for the Hospital Remuneration System ("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023. New examination and treatment methods (NUBs) are comprised of novel and innovative medicines, medical products and procedures that can be utilized by hospitals before reaching full reimbursement eligibility. The NUB process opens the path for negotiations between hospitals and health insurers for the reimbursement of ne
- SECSEC Form 6-K filed by Neovasc Inc.6-K - NEOVASC INC (0001399708) (Filer)
- SECSEC Form 6-K filed by Neovasc Inc.6-K - NEOVASC INC (0001399708) (Filer)
- NEWSBenzinga's Top Ratings Upgrades, Downgrades For January 18, 2023Upgrades According to Citigroup, the prior rating for Pegasystems Inc (NASDAQ:PEGA) was changed from Neutral to Buy. In the third quarter, Pegasystems showed an EPS of $0.34, compared to $0.40 from the year-ago quarter. At the moment, the stock has a 52-week-high of $102.50 and a 52-week-low of $29.05. Pegasystems closed at $35.62 at the end of the last trading period. Mizuho upgraded the previous rating for Oatly Group AB (NASDAQ:OTLY) from Neutral to Buy. Oatly Group earned $0.18 in the third quarter, compared to $0.07 in the year-ago quarter. The stock has a 52-week-high of $7.98 and a 52-week-low of $1.28. At the end of the last trading period, Oatly Group closed at $2.69. Barclays
- NEWSHC Wainwright & Co. Downgrades Neovasc to NeutralHC Wainwright & Co. analyst Vernon Bernardino downgrades Neovasc (NASDAQ:NVCN) from Buy to Neutral.
- SECSEC Form 6-K filed by Neovasc Inc.6-K - NEOVASC INC (0001399708) (Filer)
NVCN FAQ
6 questionsWhat does Neovasc Inc. do?
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices for cardiovascular marketplace in Europe, Canada, the United States, and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.What is the latest news on NVCN?
Quantisnow has not tracked any new filings, ratings or press releases for NVCN in the last 30 days. The most recent wire item was published on April 24, 2024.Where does NVCN stock trade?
Neovasc Inc. (NVCN) is listed on NASDAQ.What sector and industry is NVCN in?
Neovasc Inc. operates in the Health Care sector, Pharmaceuticals and Biotechnology industry.What companies are similar to NVCN?
Notable peers in the same industry include EPRX (Eupraxia Pharmaceuticals Inc.), IMV (IMV Inc.), HEXO (HEXO Corp.), ZOM (Zomedica Corp.), RVLP (RVL Pharmaceuticals plc). Compare NVCN side-by-side with any of them on Quantisnow.How can I track NVCN on Quantisnow?
Quantisnow aggregates Neovasc Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NVCN to receive live email and push alerts on every new disclosure.